RECURSION PHARMACEUTICALS, INC. Operating Lease, Payments, Use
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Lease, Payments, Use of $3.96 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePaymentsUse · last filed 2024-05-09
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2024-03-31 was $3.96M, a 61.82% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2023-12-31 was $1.91M, a 12.41% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2023-09-30 was $2.51M, a 18.58% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for the quarter ending 2023-06-30 was $3.00M, a 93.79% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2023 was $9.86M, a 38.71% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2022 was $7.11M.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2021 was $0.00.
- RECURSION PHARMACEUTICALS, INC. operating lease, payments, use for fiscal 2020 was $0.00.
| Period end | Operating Lease, Payments, Use 3 month | Operating Lease, Payments, Use 6 month | Operating Lease, Payments, Use 9 month | Operating Lease, Payments, Use 12 month |
|---|---|---|---|---|
| 2024-03-31 | $3.96M 10-Q · filed 2024-05-09 | $5.87M derived: sum of 2 quarters · filed 2024-05-09 | $8.38M derived: sum of 3 quarters · filed 2024-05-09 | $11.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.42M derived: sum of 2 quarters · filed 2024-02-29 | $7.42M derived: sum of 3 quarters · filed 2024-02-29 | $9.86M 10-K · filed 2024-02-29 |
| 2023-09-30 | $2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.51M derived: sum of 2 quarters · filed 2023-11-09 | $7.95M 10-Q · filed 2023-11-09 | $10.13M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.44M 10-Q · filed 2023-08-08 | $7.63M derived: sum of 3 quarters · filed 2024-05-09 | $9.74M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $2.44M 10-Q · filed 2024-05-09 | $4.63M derived: sum of 2 quarters · filed 2024-05-09 | $6.74M derived: sum of 3 quarters · filed 2024-05-09 | $8.29M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.30M derived: sum of 2 quarters · filed 2024-02-29 | $5.84M derived: sum of 3 quarters · filed 2024-02-29 | $7.11M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.66M derived: sum of 2 quarters · filed 2023-11-09 | $4.93M 10-Q · filed 2023-11-09 | $4.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.81M 10-Q · filed 2023-08-08 | $2.81M derived: sum of 3 quarters · filed 2024-02-29 | $2.81M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.26M 10-Q · filed 2023-05-08 | $1.26M derived: sum of 2 quarters · filed 2024-02-29 | $1.26M derived: sum of 3 quarters · filed 2024-02-29 | $1.26M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |